3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
pembrolizumab
10
Gemcitabine
8
Cyclophosphamide
7
Filgrastim
5
Docetaxel
5
Carboplatin
5
Trastuzumab
4
Surveys and Questionnaires
4
Nivolumab
4
Doxorubicin
4
Cisplatin
4
poly ICLC
3
pazopanib
3
atezolizumab
3
aldesleukin
3
Taxes
3
Radiotherapy
3
Paclitaxel
3
Oncolytic Virotherapy
3
Irinotecan
3
Ipilimumab
3
Injections
3
Drug Therapy
3
Cetuximab
3
Capecitabine
3
Albumin-Bound Paclitaxel
3
130-nm albumin-bound paclitaxel
3
spartalizumab
2
palbociclib
2
liposomal doxorubicin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
tinostamustine
×
Breast
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts